CTL has been recognized as the leader in basic science publications about (and clinical application of) ELISPOT assays, instrumentation, software, and reagent solutions. CTL is the only entity that specializes in developing ELISPOT instrumentation, assays, and their implementation in GLP compliant contract research. As such, CTL has been recognized by the Cancer Vaccine Consortium as the ELISPOT reference laboratory and has been awarded by the U.S. National Institutes of Health (NIH) a contract for the validation of the ELISPOT assay for clinical trials.
In recent years, CTL has expanded to include instrumentation for evaluating bioassays as well as reagent solutions including cryopreserved PBMC samples and serum-free media.
Because of its commitment to world-class quality and performance, CTL was awarded the 2005 “Excellence in Exporting” award by the State of Ohio’s Governor’s Office.
Today, CTL’s instrumentation and products are placed in over 30 countries, with over 350 institutes adopting the ImmunoSpot® platform for their immunological research needs.